A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Foulds, Penelope G ^a   Diggle, Peter ^b   Mitchell, J Douglas ^c   Parker, Angela ^c   Hasegawa, Masato ^d   Masuda Suzukake, Masami ^d   Mann, David M A ^e   Allsop, David ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c ROYAL PRESTON HOSPITAL   (United Kingdom)

^d TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PARKINSON DISEASE; PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SEX DIFFERENCE; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PHOSPHORYLATION; REPRODUCIBILITY OF RESULTS; ROC CURVE; SEX FACTORS;

EID: 84902894449     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02540     Document Type: Article

References (34)

1. Spillantini, M. G. et al. a-Synuclein in Lewy bodies. Nature 388, 839-840 (1997).
2. Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of a-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281, 29739-29752 (2006).
3. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95, 6469-6473 (1998).
4. Houlden, H. & Singleton, A. B. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol 124, 325-338 (2012).
5. Masliah, E. et al. Dopaminergic loss and inclusion body formation in a-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
6. Giasson, B. I. et al. Neuronal a-synucleinopathy with severe movement disorder in mice expressing A53T human a-synuclein. Neuron 34, 521-533 (2002).
7. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
8. Tolosa, E., Wenning, G. & Poewe, W. The diagnosis of Parkinson's disease. Lancet Neurol 5, 75-86 (2006).
9. Hughes, A. J., Daniel, S. E., Ben-Shlomo, Y. & Lees, A. J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861-870 (2002).
10. El-Agnaf, O. M. A. et al. a-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 18, 1315-1317 (2004).
11. Angot, E. & Brundin, P. Dissecting the potential molecular mechanisms underlying a-synuclein cell-to-cell transfer in Parkinson's disease. Parkinsonism Relat Disord 15, S143-S147 (2009).
12. Luk, K. C. et al. Pathological a-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012).
13. Tokuda, T. et al. Decreased a-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 349, 162-166 (2006).
14. Mollenhauer, B. et al. Direct quantification of CSF a-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213, 315-325 (2008).
15. Hong, Z. et al. DJ-1 and a-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726 (2010).
16. Lee, P. H. et al. The plasma a-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 113, 1435-1439 (2006).
17. Li, Q. X. et al. Plasma a-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol 204, 583-588 (2007).
18. Shi, M. et al. Significance and confounders of peripheral DJ-1 and a-synuclein in Parkinson's disease. Neurosci Lett 480, 78-82 (2010).
19. Foulds, P. G. et al. Phosphorylated a-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J 25, 4127-4137 (2011).
20. Foulds, P. G., Mann, D. M. A., Mitchell, J. D. & Allsop, D. Progress towards a molecular biomarker for Parkinson disease. Nat Rev Neurol 6, 359-361 (2010).
21. Alemayehu, D. & Zou, K. H. Applications of ROC analysis in medical research: recent developments and future directions. Acad Radiol 19, 1457-1464 (2012).
22. Bartels, T., Choi, J. G. & Selkoe, D. J. a-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107-110 (2011).
23. El-Agnaf, O. M. A. et al. Detection of oligomeric forms of a-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 20, 419-425 (2006).
24. Foulds, P. G. et al. Post mortem cerebrospinal fluid a-synuclein levels are raised in multiple system atrophy and distinguish this from the other a-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol Dis 45, 188-195 (2012).
25. Okochi, M. et al. Constitutive phosphorylation of the Parkinson's disease associated a-synuclein. J Biol Chem 275, 390-397 (2000).
26. Zhou, J. et al. Changes in the solubility and phosphorylation of a-synuclein over the course of Parkinson's disease. Acta Neuropathol 121, 695-704 (2011).
27. Paleologou, K. E. et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of a-synuclein. J Biol Chem 283, 16895-16905 (2008).
28. Waxman, E. A. & Giasson, B. I. Characterization of kinases involved in the phosphorylation of aggregated a-synuclein. J Neurosci Res 89, 231-247 (2011).
29. Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H. & Del Tredici, K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318, 121-134 (2004).
30. Beach, T. G. et al. Multi-organ distribution of phosphorylated a-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119, 689-702 (2010).
31. Gibb, W. R. G. & Lees, A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiat 51, 745-752 (1998).
32. Sasakawa, H. et al. Ultra-high field NMR studies of antibody binding and sitespecific phosphorylation of a-synuclein. Biochem Biophys Res Commun 363, 795-799.
33. Laird, N. M. & Ware, J. H. Random-effects models for longitudinal data. Biometrics 38, 963-974 (1982).
34. Diggle, P. J. An approach to the analysis of repeated measurements. Biometrics 44, 959-971 (1988).